Dr Alastair Smith leads a Yorkshire-based drug developer which is striving to find treatments for a wide range of cancers, writes Deputy Business Editor Greg Wright.
It cannot claim to be a household name, but Avacta’s work to develop a form of chemotherapy without side effects could be about to cause ripples around the world.
The Yorkshire-based drug developer, which is working on cures for lung, breast, gastric and bowel cancer, plans to start its first human clinical studies in late 2020.
Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.